linjc16/ctgov huggingface dataset:
Comparison of Sucess of Pulpotomy, Direct Pulp Capping and Indirect Pulp Capping Modalities Using MTA in Primary Teeth

Study Overview
=================
Brief Summary
-----------------
450 healthy children with primary teeth of deep carious lesions without signs or symptomes of irreverisible pulp damage was selected randompy divoded into 3 groups each of 150 children that inder go vital pulp therapy through pulpotomy,direct pulp capping or indirect pulp capping using MTA as capping material for each modality then followed up for 2 years or more

Official Title
-----------------
Comparison of Sucess of Pulpotomy, Direct Pulp Capping and Indirect Pulp Capping Modalities Using MTA in Primary Teeth (2 Years Follow up)

Conditions
-----------------
Deep Caries

Intervention / Treatment
-----------------
* Other: Vital pulp therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children Aged from 3 to 10 years old Deep cariuos primary tooth Exclusion Criteria: Primary teeth with any signs or syptoms of irreversible pulpitis Primary teeth of any signs or symptomes of vitality loss Primary teeth near to exfoliation

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MTA pulpotomy<br>Usuing MTA as capping material for cervical pulpotomy as a treatment option for deep carious primary teeth with signs and symptoms of reversible pulpitis in presence of pulp exposure | Other: Vital pulp therapy<br>* Vital pulp therapy different modalities for management of deep carious lesion in primary teeth<br>|
| Experimental: MTA direct pulp capping<br>Using MTA as capping material in case of trearment of deep carious primary teeth with signs and symptoms of reversible pulpitis with presence of pulp exposure | Other: Vital pulp therapy<br>* Vital pulp therapy different modalities for management of deep carious lesion in primary teeth<br>|
| Experimental: MTA indirect pulp capping<br>Using MTA as indirect capping material for treatment of deep carious primary teeth with signs and symptoms of reversible pulpitis | Other: Vital pulp therapy<br>* Vital pulp therapy different modalities for management of deep carious lesion in primary teeth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tenderness | Precence or abscence | 2 years | 
| Abcess | Precence or abscence | 2 years | 
| Fistula | Precence or abscence | 2 years | 
| lamina dura | Intact or distorted | 2 years | 
| Periapical radiographic radiolucency | Precence or abcencs | 2 years |
Ultrasound Assessment of Residual Gastric Content in Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
This prospective observational study aims to assess whether ultrasound assessment of gastric content may be useful for the monitoring of the gastric residual content in critically ill patients

Official Title
-----------------
Ultrasound Assessment of Residual Gastric Content in Critically Ill Patients

Conditions
-----------------
Critically Ill Patients

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound examination of the antrum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients under mechanical ventilation and enteral feeding through a gastric tube since >48 h Exclusion Criteria: Digestive hemorrhage Contra-indication to prokinetic drugs Enteral feeding through jejunostomy or gastrostomy Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in antral cross sectional area measured by ultrasonography after suctioning gastric volume | Ultrasound measurement of antral area and qualitative assessment | prior to and immediately after suctioning of gastric content volume through a gastric tube | 
| Change in antral area after administration of prokinetic drug | If aspirated gastric content volume was > 250 ml, only 250 ml will be reinjected into the stomach and a prokientic drug will be administered (current protocol in our units). Antral area will be measured prior to and 90 min after the start of the infusion | Ultrasound assessment of gastric content after reinjection of suctioned gastric content and 1h30 later (1 h after the end of the infusion of prokinetic drug) |
UEMR vs. CEMR for Diminutive Non-pedunculated Colorectal Polyps

Study Overview
=================
Brief Summary
-----------------
This clinical trial is being conducted to compare the efficacy and safety of two standard methods of polypectomy，Conventional Endoscopic Mucosal Resection（EMR）and Underwater Endoscopic Mucosal Resection（UEMR），for small colorectal polyps.

Official Title
-----------------
Efficacy and Safety of Underwater vs. Conventional Endoscopic Mucosal Resection for the Treatment of Diminutive Non-pedunculated Colorectal Polyps：A Multicenter Randomized Clinical Trial

Conditions
-----------------
Colonic Polyps

Intervention / Treatment
-----------------
* Behavioral: Underwater EMR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age between 18-75 years old with non-pedunculated colonic polyps (measuring between 4 and 9mm), who willing to participate in this study. Exclusion Criteria: pregnancy, inflammatory bowel disease, familial polyposis the use of anticoagulant therapy or antiplatelet therapy the absence of informed patient consent. Polyps showing signs of deep submucosal invasion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Underwater EMR<br>The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection. | Behavioral: Underwater EMR<br>* Polypectomy is performed under full water emersion without the use of submucosal injection.<br>|
| No Intervention: Traditional EMR<br>The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete resection rate | complete resection rate is defined as a complete en bloc resection of a lesion with tumor-free lateral and vertical margins. | 7 days | 
| En bloc resection rate | En bloc resection rate was defined as the entire lesion could be removed in 1 piece instead of piecemeal resection. | immediately | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event rate | Including bleeding and perforation , etc. | 14 days | 
| Procedure time | Time to execute the program | 24 hours |
18751-Sun Protection Factor Assay.

Study Overview
=================
Brief Summary
-----------------
To evaluate the Sun Protection Factor (SPF) efficacy on human skin.

Official Title
-----------------
Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose

Conditions
-----------------
Sunscreening Agents

Intervention / Treatment
-----------------
* Drug: Coppertone(BAY987517)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing. - Male or female - Aged between 18-70 years old. - Good health - Signed and dated Informed Consent Form - Signed and dated Health Insurance Portability and Accountability Authorization (HIPAA) Form - An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose) Exclusion Criteria: - Subjects on test at any other research laboratory or clinic. - Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light. - PRe-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study. - Pre-existing other medical conditions (e.g. adult asthma. diabetes). - Treatment with antihistamines or corticosteroids within one week prior to initiation of the test. - Treatment with antibiotics within two weeks prior to initiation of the test - Chronic medication which could affect the results of the study. - Known pregnant or nursing women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BAY 987517<br>Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application | Drug: Coppertone(BAY987517)<br>* Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.Formulation number - SR16-02.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minimal Erythema Dose(MED) |  | Up to 15 minutes | 
| Minimal Persistent Pigment Darkening Dose (MPPD) |  | Up to 15 minutes |
Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesis that exercise training would potentiate the effects of cardiac resynchronization therapy in heart failure patients.

Official Title
-----------------
Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Other: exercise training and/or CRT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: QRS> 150 ms or 120-150ms associated dyssynchrony The etiology can be idiopathic, ischemic, hypertensive and Chagas' disease Ejection fraction <35% The optimal pharmacological treatment for heart failureExclusion Criteria: Exclusion Criteria: Patients with pulmonary diseases, neurological diseases, renal, skeletal muscle diseases Patients with contraindications to implant a cardiac pacemaker Pregnancy New York Heart Association functional class IV Atrial fibrillation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Healthy People<br>Control group | |
| Experimental: Untrained CRT<br>Untrained CRT patients | Other: exercise training and/or CRT<br>* Three 40-minute exercise sessions per week on a treadmill for four months<br>* Other names: Exercise-trained CRT patients;|
| Experimental: Exercise trained + CRT<br>Exercise-trained CRT patients | Other: exercise training and/or CRT<br>* Three 40-minute exercise sessions per week on a treadmill for four months<br>* Other names: Exercise-trained CRT patients;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sympathetic nerve activity | Sympathetic nerve activity will be assessed by microneurography | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak oxygen consumption | Peak oxygen consumption will be determined by cardiopulmonary exercise testing | 4 months | 
| Quality of life | Quality of life will be assessed by questionnaire | 4 months | 
| Blood inflammatory markers | Blood inflammatory markers will be assessed by venipuncture | 4 months | 
| skeletal muscle strength | Muscular evaluation will be done muscle gene expression | 4 months | 
| Muscle Blood Flow | Forearm blood flow will be assessed by venous occlusion plethysmography | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac resynchronization therapy (CRT)
Evaluation of the Safety and Efficacy of the AnapnoGuard 100 System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety of using the AnapnoGuard 100 system during the course of mechanical ventilation and intubation of critical care patients in Intensive Care Unit.

Official Title
-----------------
The Safety of Using the AnapnoGuard 100 System in Intubated Critical Care Patients

Conditions
-----------------
Intubation Complications

Intervention / Treatment
-----------------
* Device: AnapnoGuard 100 System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 21 (men and women); Patient is admitted to ICU and expected to receive mechanical ventilation for more than 12 hours Absence of clear signs of pneumonia and lung contusion on chest X ray; For study patients, connection of the ETT to the AnapnoGuard system less than 6 hours from intubation initiation; No fever or fever from a known non chest/lung origin; Exclusion Criteria: Patients who had been treated with mechanical ventilation during the last 3 months; Patients with facial, oropharyngeal or neck trauma BMI > 40 Pregnant women Patients ventilated in prone position Difficult intubation (defined as more than 3 intubation attempts)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study Group<br>Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System | Device: AnapnoGuard 100 System<br>* AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.<br>|
| No Intervention: Control Group<br>Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of AE (adverse events) and SAE (serious adverse events) |  | participants will be followed for the entire duration of intubation (an expected average of 8 days) |
Glidescope Videolaryngoscope and Macintosh Laryngoscope in Children

Study Overview
=================
Brief Summary
-----------------
The main objective of this study was to evaluate the intubation time of Glidescope compared with Macintoch laryngoscope in pediatric patients, ease of intubation, and cardiovascular changes during intubation.

Detailed Description
-----------------
This was a prospective randomized clinical study to be performed in pediatric patients older than 1 years who are undergoing surgical procedures requiring endotracheal intubation. Time to endotracheal intubation was compared between patients intubated using a GlideScope® video laryngoscope, and those intubated by standard direct laryngoscopy. The main objective of this study was to evaluate the intubation time of Glidescope compared with Macintoch laryngoscope in pediatric patients, ease of intubation, and cardiovascular changes during intubation.

Official Title
-----------------
Comparison of Glidescope Videolaryngoscope and Macintosh Laryngoscope in Children Aged >1 Years

Conditions
-----------------
Anesthesiology, Pediatrics

Intervention / Treatment
-----------------
* Device: Endotracheal intubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status I-II patients, scheduled for elective surgery under general anesthesia with endotracheal intubation Exclusion Criteria: risk of pulmonary aspiration, presence of difficult intubation, emergency surgery, cardiovascular disease, respiratuar disease, hemodynamic instability.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Glidescope<br>A device for endotracheal intubation | Device: Endotracheal intubation<br> <br> * Other names: Glidescope video laryngoscope;|
| Active Comparator: Macintosh laringoscope<br>A device for endotracheal intubation | Device: Endotracheal intubation<br> <br> * Other names: Glidescope video laryngoscope;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Intubation | Time from laryngoscopy to intubation | Intraoperative |
Acceptability and Tolerance Study of a Thickener

Study Overview
=================
Brief Summary
-----------------
This is a prospective, acceptability study to evaluate the gastrointestinal tolerance and compliance of a thickener for the management of reflux, GORD and dysphagia

Detailed Description
-----------------
To evaluate the gastrointestinal tolerance and compliance of a thickener for 7 days for the submission to the Advisory Committee for Borderline Substances (ACBS).

Official Title
-----------------
Evaluation of the Acceptability (Including Gastrointestinal Tolerance, Compliance) of a Thickener

Conditions
-----------------
Dysphagia

Intervention / Treatment
-----------------
* Dietary Supplement: Resource Thicken up Junior


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: I. Infants and children aged 6 months and over who require a thickener for reflux, GORD, dysphagia II. Infants and children already on a thickener for the management of reflux, GORD and dysphagia III. Parents to avoid introducing new weaning/ new foods (for the older infants) whilst on the thickener for 1 week when measuring GI tolerance and thickener intake IV. Willingly given, written, informed consent from patient or parent/guardian Exclusion Criteria: I. Inability to comply with the study protocol, in the opinion of the investigator. II. Contraindications to any feed ingredients (see nutritional table and ingredients list) III. Allergy to milk (thickener is made in a factory that handles milk) IV. Children under the age of 6 months of age V. Emergencies VI. Participation in another interventional study -

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastrointestinal tolerance | Measure using daily diary | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participant compliance | Daily intake using diary | 7 days |